Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry

Parkinsonism and Related Disorders

Volumn 21, Issue 8, 2015, Pages 871-876

  Buongiorno, Maríateresa ^a,b,c   Antonelli, Francesca ^a,b,c   Cámara, Ana ^a,b,c   Puente, Victor ^d   de Fabregues Nebot, Oriol ^e   Hernandez Vara, Jorge ^e   Calopa, Matilde ^a   Pascual Sedano, Berta ^c,d   Campolongo, Antonia ^c,d   Valldeoriola, Francesc ^a,b,c   Tolosa, Eduardo ^a,b,c   Kulisevsky, Jaime ^c,d,f   Martí, Maria Jose ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f UNIVERSITAT OBERTA DE CATALUNYA   (Spain)

Author keywords

Levodopa carbidopa intestinal gel; Long term treatment; Motor fluctuations; Non motor symptoms; Parkinson disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ANTIPARKINSON AGENT; CARBIDOPA; GEL; LEVODOPA;

ADULT; AGED; AKATHISIA; ANOREXIA; ARTICLE; BEZOAR; BODY WEIGHT DISORDER; CELLULITIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; DAYTIME SOMNOLENCE; DIGESTIVE TUBE; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HALLUCINATION; HUMAN; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTRADUODENAL DRUG ADMINISTRATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; COMPLICATION; DUODENUM; DYSKINESIAS; FOLLOW UP; GEL; MIDDLE AGED; PARENTERAL DRUG ADMINISTRATION; REGISTER; SPAIN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CARBIDOPA; DUODENUM; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; INFUSIONS, PARENTERAL; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; REGISTRIES; SPAIN; TREATMENT OUTCOME;

EID: 84937512510     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.05.014     Document Type: Article

References (29)

1. Schrag A., Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000, 123:2297-2305.
2. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 2000, 47:S2-S9.
3. Mouradian M.M., Heuser I.J., Baronti F., Fabbrini G., Juncos J.L., Chase T.N. Pathogenesis of dyskinesias in Parkinson's disease. Ann. Neurol. 1989, 25:523-526.
4. Wenzel K., Homann C.N., Fabbrini G., Colosimo C. The role of subcutaneous infusion of apomorphine in Parkinson's disease. Expert Rev. Neurother. 2014, 14:833-843.
5. Castrioto A., Lozano A.M., Poon Y.Y., Lang A.E., Fallis M., Moro E. Ten year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch. Neurol. 2011, 68:1550-1556.
6. Pedersen S.W., Clausen J., Gregerslund M.M. Practical guidance on how to handle levodopa/carbidopa intestinal gel therapy of advanced PD in a movement disorder clinic. Open Neurol. J. 2012, 6:37-50.
7. Olanow C.W., Kieburtz K., Odin P., Espay A.J., Standaert D.G., Fernandez H.H., et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014, 13:141-149.
8. Kurth M.C., Tetrud J.W., Tanner C.M., Irwin I., Stebbins G.T., Goetz G.T., et al. Double-blind, placebo controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with "on-off" fluctuations. Neurology 1993, 43:1698-1703.
9. Antonini A., Isaias I.U., Canesi M., Zibetti M., Mancini F., Manfredi L., et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov. Disord. 2007, 15:1145-1149.
10. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov. Disord. 2009, 15:993-1000. French Duodopa Study.
11. Nyholm D. Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat. Disord. 2012, 18:916-929.
12. Cáceres-Redondo M.T., Carrillo F., Lama M.J., Huertas-Fernández I., Vargas-González L., Carballo M., et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. J.Neurol. 2014, 261:561-569.
13. Zibetti M., Merola A., Artusi C.A., Rizzi L., Angrisano S., Reggio D., et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Eur. J. Neurol. 2014, 21:312-318.
14. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 2010, 25:2649-2653.
15. Busner J., Targum S.D. The clinic global impression scale applying a research tool in clinical practice. Psychiatry (Edgmont) 2007, 4:28-37.
16. Fahn S., Elton R.L. Unified Parkinson's disease rating scale. Recent Developments in Parkinson's Disease 1987, 153-163. Members of the UPDRS Development Committee, McMillan Health Care Information, Florham Park, NJ. S. Fahn, C.D. Marsden, D.B. Calne, A. Lieberman (Eds.).
17. Schwab and England Scale Schwab RS, England AC Projection technique for evaluating surgery in Parkinson's disease. Third Symposium on Parkinson's Disease 1969, E and S Livingstone, Edinburgh. F.J. Gillingham, I.M.L. Donaldson (Eds.).
18. Antonini A., Odin P., Opiano L., Tomantschger V., Pacchetti C., Pickut B., et al. Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J.Neural Transm. 2013, 120:1553-1558.
19. Pickut B.A., van der Linden C., Dethy S., Van De Maele H., de Beyl D.Z. Intestinal levodopa infusion: the Belgian experience. Neurol. Sci. 2014, 35:861-866.
20. Sensi M.C., Preda F., Trevisani L., Contini E., Gragnaniello D., Capone J.G., et al. Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J.Neural Transm. 2014, 121:633-642.
21. Fernandez H.H., Standaert D.G., Vanagunas A., Hauser R.A., Lang A., Fung V.S., et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: final 12-months, open-label results. Mov. Disord. 2015, 30:500-509.
22. Nyholm D., Johansson A., Aquilonius S.M., Hellquist E., Lennernas H., Asmark H. Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease. Clin. Neuropharmacol. 2012, 35:6-14.
23. Nutt J.G. Continuous levodopa infusion is better-for now. Mov. Disord. 2015, 30:443-445.
24. Honig H., Antonini A., Martinez-Martin P., Forgacs I., Faye G.C., Fox T., et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov. Disord. 2009, 24:1468-1474.
25. Zibetti M., Rizzone M., Merola A., Angrisano S., Rizzi L., Montanaro E., et al. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease. Acta Neurol. Scand. 2013, 127:28-32.
26. Nyholm D., Jansson R., Willows T., Remahl I. Long term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005, 65:1506-1507.
27. Nilsson D., Nyholm D., Aquilonius S.M. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol. Scand. 2001, 104:343-348.
28. Fernandez H.H., Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr. Med. Res. Opin. 2011, 27:907-919.
29. Müller T., van Laar T., Cornblath D., Odin P., Klostermann F., Grandas F., Ebersbach G., Urban P., et al. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat. Disord. 2013, 19:501-507.